3D-011 is under clinical development by 3D Medicines and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 3D-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

3D-011 overview

3D-011 is under development for the treatment of advanced or metastatic malignant solid tumors including advanced or metastatic hepatocellular carcinoma, advanced renal cell carcinoma and metastatic castration-resistant prostate cancer. It acts by targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor are receptor tyrosine kinases (PDGFR). It is administered through intravenous drip route.

3D Medicines overview

3D Medicines is a precision medicine company which provides cancer precision medical treatment. The company provides ANDiS SARS-CoV-2 detection kit and the ANDiS SARS-CoV-2 and influenza A/B detection kit. The company offers cancer diagnosis and treatment through the integration of biological characteristics, clinical diagnosis and treatment, and drug research and development data mining application. It offers precision cancer prevention, precision cancer diagnosis, and precision drug development. 3D Medicines offers services for different people, which covers tumor tissue and blood samples. The company also operates in the field of drug development that covers immunotherapy and other biomarker-Driven targeting therapy. It has operations in China, Japan and the US. 3D Medicines is headquartered in Shanghai, China.

For a complete picture of 3D-011’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.